Trellis Bioscience, Inc. has taken a significant step in its funding strategy by filing a new offering under Rule 506(b) of the Securities Act. This offering aims to raise capital through equity and convertible notes, reflecting the company's ongoing efforts to secure financial resources for its biotechnology initiatives.
As a player in the biotechnology sector, Trellis Bioscience is focused on developing innovative solutions. The filing, dated October 21, 2026, indicates that the company is looking to bolster its financial position amidst a competitive landscape.
Background
Trellis Bioscience, Inc. is incorporated in Delaware and operates out of Menlo Park, California. The company has undergone name changes over the years, previously known as Trellis Bioscience LLC and Trellis Bioscience Inc. The firm is categorized under the biotechnology industry, which has seen a surge in funding as companies pursue groundbreaking research and development.
What the Filing Says
The recent SEC filing reveals that Trellis Bioscience is utilizing Rule 506(b) to create a safer harbor for its private offering. The offering includes equity securities and convertible notes with 20% warrant coverage. The total offering amount is listed as indefinite, with $4,094,500 already sold, while the remaining amount is also indefinite.
Impact
This offering may affect various stakeholders, including existing investors and potential new investors. The filing indicates that there are currently 27 investors involved in the offering, all of whom are accredited. The move is likely to enhance Trellis's financial flexibility, allowing it to pursue further development in its biotechnology projects.
What's Next
The filing does not specify what happens next regarding the use of proceeds or future plans. However, the company’s ongoing efforts to secure funding suggest that it will continue to focus on advancing its biotechnology initiatives.
Source: SEC Accession Number 0000929638-26-003973